Latest News about AMGN
Recent news which mentions AMGN
2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever
April 17, 2025
From Motley Fool
Sandoz Files Lawsuit Alleging Amgen Illegally Blocked Biosimilar Competition For Its Blockbuster Arthritis Drug
April 14, 2025
From Benzinga
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies
April 11, 2025
From Benzinga
Rule Breaker Investing: Essays From Yesterday, Vol. 7
April 10, 2025
From Motley Fool
Trump Hints At 'Major Tariff' On Imported Pharmaceuticals: Pfizer, Eli Lilly, Amgen And Other Stocks Tumble In Wednesday Pre-Market
April 09, 2025
From Benzinga
P/E Ratio Insights for Amgen
April 07, 2025
From Benzinga
3 Dividend Stocks to Buy and Hold for the Next Decade
April 06, 2025
From Motley Fool
2 Dividend Stocks to Buy Hand Over Fist in April
April 05, 2025
From Motley Fool
Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks
April 04, 2025
From Benzinga
Nasdaq 100 Enters Bear Market, Dow In Correction Territory, Traders Await Fed Chair Powell's Remarks
April 04, 2025
From Benzinga
FDA Approves Amgen's Uplizna As First Drug For Chronic Immune-Mediated Fibroinflammatory Disorder
April 04, 2025
From Benzinga
From Benzinga
Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday
April 03, 2025
From Motley Fool
From Motley Fool
P/E Ratio Insights for Amgen
April 02, 2025
From Benzinga
2 Surefire Dividend Stocks That Could Pay You for Life
March 28, 2025
From Motley Fool
Which Dow Jones Stock Is Cheaper, Amgen or Merck?
March 28, 2025
From Motley Fool
Why Pharma and Biotech Stocks Got Thrashed on Tuesday
March 25, 2025
From Motley Fool
Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen
March 22, 2025
From Benzinga
10 Health Care Stocks Whale Activity In Today's Session
March 21, 2025
From Benzinga
From Benzinga
Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress
March 20, 2025
From Benzinga
From Motley Fool
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.